CN102368905B - 酸性神经酰胺酶的向溶酶体抑制剂 - Google Patents

酸性神经酰胺酶的向溶酶体抑制剂 Download PDF

Info

Publication number
CN102368905B
CN102368905B CN200980154007.6A CN200980154007A CN102368905B CN 102368905 B CN102368905 B CN 102368905B CN 200980154007 A CN200980154007 A CN 200980154007A CN 102368905 B CN102368905 B CN 102368905B
Authority
CN
China
Prior art keywords
compound
purposes
alkyl
cancer
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980154007.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102368905A (zh
Inventor
A·别拉夫斯基
柏爱萍
Z·M·肖尔茨
Y·A·哈努恩
J·诺里斯
柳湘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MUSC Foundation for Research and Development
Original Assignee
MUSC Foundation for Research and Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MUSC Foundation for Research and Development filed Critical MUSC Foundation for Research and Development
Publication of CN102368905A publication Critical patent/CN102368905A/zh
Application granted granted Critical
Publication of CN102368905B publication Critical patent/CN102368905B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN200980154007.6A 2008-11-06 2009-11-06 酸性神经酰胺酶的向溶酶体抑制剂 Expired - Fee Related CN102368905B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11185208P 2008-11-06 2008-11-06
US61/111,852 2008-11-06
PCT/US2009/063586 WO2010054223A1 (en) 2008-11-06 2009-11-06 Lysosomotropic inhibitors of acid ceramidase

Publications (2)

Publication Number Publication Date
CN102368905A CN102368905A (zh) 2012-03-07
CN102368905B true CN102368905B (zh) 2015-04-01

Family

ID=42153265

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980154007.6A Expired - Fee Related CN102368905B (zh) 2008-11-06 2009-11-06 酸性神经酰胺酶的向溶酶体抑制剂

Country Status (9)

Country Link
US (1) US8697379B2 (enExample)
EP (1) EP2348839B1 (enExample)
JP (1) JP5721631B2 (enExample)
CN (1) CN102368905B (enExample)
AU (1) AU2009313400A1 (enExample)
BR (1) BRPI0921278A2 (enExample)
CA (1) CA2742866C (enExample)
RU (1) RU2011117722A (enExample)
WO (1) WO2010054223A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2585775C (en) 2004-10-29 2013-10-01 Musc Foundation For Research Development Cationic ceramides, and analogs thereof, and their use for preventing or treating cancer
US8592419B2 (en) 2004-10-29 2013-11-26 Musc Foundation For Research Development Ceramides and apoptosis-signaling ligand
WO2010054223A1 (en) 2008-11-06 2010-05-14 Musc Foundation For Research Development Lysosomotropic inhibitors of acid ceramidase
AU2009332952A1 (en) * 2008-12-30 2011-07-21 Musc Foundation For Research Development Sphingo-guanidines and their use as inhibitors of sphingosine kinase
SI2753346T1 (sl) 2011-09-07 2020-09-30 Mount Sinai School Of Medicine Ceramidaza in diferenciacija celic
ITMI20120921A1 (it) 2012-05-28 2013-11-29 Fond Istituto Italiano Di Tec Nologia 45 Inibitori della ceramidasi acida e loro usi come medicamenti
ITMI20120923A1 (it) 2012-05-28 2013-11-29 Fond Istituto Italiano Di Tec Nologia 45 Inibitori della ceramidasi acida e loro usi come medicamenti
HUE051020T2 (hu) * 2012-06-01 2021-01-28 Icahn School Med Mount Sinai A ceramid szintjei a fertõzések kezelésében és megelõzésében
WO2014160390A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
WO2015119393A1 (ko) * 2014-02-04 2015-08-13 (주)네오팜 발모촉진용 또는 탈모방지용 조성물
KR20150091983A (ko) * 2014-02-04 2015-08-12 (주)네오팜 발모촉진용 또는 탈모방지용 조성물
EP3143009B1 (en) 2014-05-12 2019-09-18 Fondazione Istituto Italiano di Tecnologia Substituted benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments
WO2015173168A1 (en) 2014-05-12 2015-11-19 Fondazione Istituto Italiano Di Tecnologia Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments
WO2018200931A1 (en) * 2017-04-28 2018-11-01 University Of Virginia Patent Foundation Compositions and methods for treating cancer
CN110598636B (zh) * 2019-09-09 2023-01-17 哈尔滨工业大学 一种基于特征迁移的舰船目标识别方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101027069A (zh) * 2003-11-28 2007-08-29 宝生物工程株式会社 神经酰胺酶抑制剂
US20080045470A1 (en) * 2004-10-29 2008-02-21 Alicja Bielawska Ceramides and Apoptosis-Signaling Ligand

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2515465A (en) 1946-03-22 1950-07-18 Merck & Co Inc Preparation of 2-alkyl-4-isopropylidene-5(4)-oxazolones
GB630712A (en) 1946-03-22 1949-10-19 Merck & Co Inc Process of preparing intermediates useful in the preparation of penicill amine
GB844431A (en) * 1957-12-07 1960-08-10 Boehringer & Soehne Gmbh Injectable aqueous solutions of chloramphenicol
US3466292A (en) 1966-05-13 1969-09-09 Upjohn Co Diazatricyclododecanediones and diazatricyclododecadiendiones
GB1307539A (en) * 1970-06-25 1973-02-21 Smith Kline French Lab Thiourea derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
DE2408813A1 (de) 1974-02-23 1975-09-04 Agfa Gevaert Ag N-carbamoyloxypyridiniumsalze und verfahren zur herstellung derselben
US4481203A (en) 1977-04-05 1984-11-06 Taiho Pharmaceutical Company, Limited Composition containing 1-(n-hexylcarbamoyl)-5-fluorouracil and uracil
DE2817494A1 (de) 1977-05-03 1978-11-09 Continental Pharma Aminoalkohol-derivat
US4151198A (en) 1978-06-02 1979-04-24 American Cyanamid Company Resolution of N-acyl-DL (+)-phenylalanines
US4283541A (en) 1980-05-27 1981-08-11 Usv Pharmaceutical Corporation Pyridylacyl-hydroxamates
US4544670A (en) 1982-08-24 1985-10-01 William H. Rorer, Inc. Method of treating coccidiosis with acyl guanidines
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4937232A (en) 1986-09-15 1990-06-26 Duke University Inhibition of protein kinase C by long-chain bases
EP0310545A3 (de) 1987-09-02 1989-07-26 Ciba-Geigy Ag Cyanoguanidine als Härter für Epoxidharze
US5262568A (en) 1990-03-02 1993-11-16 State Of Oregon Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
US5679350A (en) 1992-05-28 1997-10-21 The University Of Toledo Method of delivery of a medicament to a cancer cell using a pathway of plasminogen activator material
US5369030A (en) 1992-09-11 1994-11-29 Duke University Method of inducing cellular differentiations and altering cell phenotype using ceramide analogs
WO1995006037A1 (en) * 1993-08-27 1995-03-02 Vrije Universiteit New imidazole derivatives having agonistic or antagonistic activity on the histamine h3 receptor
WO1997010817A1 (en) 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US5830916A (en) 1996-05-23 1998-11-03 Duke University Inhibitor of ceramidase
DE19621038A1 (de) 1996-05-24 1997-11-27 Boehringer Ingelheim Kg Aminoguanidine, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten
US6649362B2 (en) 1997-09-08 2003-11-18 Medvet Science Pty. Ltd. Screening method for an agent having an effect on a sphingosine kinase signaling pathway
AU765809B2 (en) 1998-02-12 2003-10-02 Emory University Sphingolipid derivatives and their methods of use
JP2002529068A (ja) 1998-11-06 2002-09-10 マスク ファウンデーション フォー リサーチ デヴェロップメント Ｆａｓ−誘導アポトーシスを用いた腫瘍の治療方法
US6756504B2 (en) 2000-04-19 2004-06-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingolipids
AU2001252506A1 (en) 2000-04-19 2001-10-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingolipids
US6696081B2 (en) 2000-06-09 2004-02-24 Duke University Carbohydrate based lipid compositions and supramolecular structures comprising same
JP2004526666A (ja) 2000-09-11 2004-09-02 マスク ファウンデーション フォー リサーチ デヴェロップメント アポトーシスの選択的誘導によって腫瘍を治療するための組成物及び方法
US20050043534A1 (en) 2001-07-11 2005-02-24 Alicja Bielawska Modulators of ceramidase and methods of used based thereon
JP2004210733A (ja) * 2003-01-07 2004-07-29 Kyowa Hakko Kogyo Co Ltd アリールスルファマート誘導体
JP2006516603A (ja) * 2003-01-27 2006-07-06 ファイザー・プロダクツ・インク イソチアゾール誘導体
WO2004074247A2 (en) 2003-02-19 2004-09-02 Endacea, Inc. A1 adenosine receptor antagonists
HRP20120901T1 (hr) 2004-03-05 2012-12-31 F. Hoffmann - La Roche Ag Diaminopirimidini kao p2x3 i p2x2/3
JP2005336174A (ja) * 2004-04-27 2005-12-08 Santen Pharmaceut Co Ltd 変形性関節症治療剤
CA2585775C (en) 2004-10-29 2013-10-01 Musc Foundation For Research Development Cationic ceramides, and analogs thereof, and their use for preventing or treating cancer
JP2006298807A (ja) * 2005-04-19 2006-11-02 Lead Chemical Co Ltd 新規化合物及びその用途
CA2612338C (en) 2005-06-17 2015-02-03 Apogee Biotechnology Corporation Sphingosine kinase inhibitors
JP2009532367A (ja) * 2006-03-31 2009-09-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ４受容体のモジュレーターとしてのベンゾイミダゾール−２−イルピリジン
CN101600686A (zh) * 2006-12-13 2009-12-09 先灵-普劳有限公司 氯霉素、甲砜霉素及其类似物的水溶性前药
WO2010054223A1 (en) 2008-11-06 2010-05-14 Musc Foundation For Research Development Lysosomotropic inhibitors of acid ceramidase
AU2009332952A1 (en) 2008-12-30 2011-07-21 Musc Foundation For Research Development Sphingo-guanidines and their use as inhibitors of sphingosine kinase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101027069A (zh) * 2003-11-28 2007-08-29 宝生物工程株式会社 神经酰胺酶抑制剂
US20080045470A1 (en) * 2004-10-29 2008-02-21 Alicja Bielawska Ceramides and Apoptosis-Signaling Ligand

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Novel analogs of d-e-MAPP and B13. Part 1: Synthesis and evaluation as potential anticancer agents;Zdzislaw M. Szulc等;《Bioorganic & Medicinal Chemistry》;20080115;第16卷(第2期);第1015-1031页 *

Also Published As

Publication number Publication date
WO2010054223A1 (en) 2010-05-14
CA2742866C (en) 2017-10-24
BRPI0921278A2 (pt) 2015-08-25
US20110251197A1 (en) 2011-10-13
EP2348839A1 (en) 2011-08-03
CN102368905A (zh) 2012-03-07
JP5721631B2 (ja) 2015-05-20
HK1167999A1 (en) 2012-12-21
EP2348839B1 (en) 2017-04-05
JP2012508249A (ja) 2012-04-05
EP2348839A4 (en) 2012-04-04
US8697379B2 (en) 2014-04-15
AU2009313400A1 (en) 2010-05-14
CA2742866A1 (en) 2010-05-14
RU2011117722A (ru) 2012-12-20

Similar Documents

Publication Publication Date Title
CN102368905B (zh) 酸性神经酰胺酶的向溶酶体抑制剂
US20120035268A1 (en) Sphingo-guanidines and their use as inhibitors of sphingosine kinase
US5994361A (en) Substituted purinyl derivatives with immunomodulating activity
CA2728219C (en) Diglycidic ether derivative therapeutics and methods for their use
US20050043534A1 (en) Modulators of ceramidase and methods of used based thereon
US8592419B2 (en) Ceramides and apoptosis-signaling ligand
JP7041673B2 (ja) Ｎ－アシルエタノールアミド誘導体およびその使用
WO2007136635A1 (en) Enhancement of radiation therapy and/or chemotherapy with acid ceramidase modulators
US8093393B2 (en) Cationic ceramides, and analogs thereof, and their use for preventing or treating cancer
WO2021004422A1 (zh) 小分子PI4KIIIα抑制剂组合物、其制备方法及用途
HK1167999B (zh) 酸性神經酰胺酶的向溶酶體抑制劑
KR20160146689A (ko) 파킨슨병을 치료하기 위한 도파민 효능제 및 l-dopa 유도체를 포함하는 조성물
KR20020042606A (ko) 엔-아세틸 파이토스핑고신과 다이메틸 파이토스핑고신을유효 성분으로 포함하는 방사선 치료 민감제 조성물
EP4232035A1 (en) Methods to sensitize tumors to treatment by immunotherapy
CN105503741A (zh) 一种氨基甲酰尿嘧啶衍生物及其应用
JP6791977B2 (ja) 骨格筋の肥大剤としてのフロスタン−３オール誘導体
WO2008112251A1 (en) Cyclopropyl-containing polyamine analogs as disease therapies
US20240216354A1 (en) Immunomodulatory imide drugs as zeta-chain-associated protein kinase 70 (zap70) agonists and uses thereof
ES2384852B1 (es) Éteres de hidroxitirosol
WO2024124043A1 (en) Multicyclic compounds
HK40074190B (zh) 小分子PI4KIIIα抑制剂组合物、其制备方法及用途
WO2005118522A1 (en) Monomethylphytosphingosine- polyethylenegly col and the composition for anti-cancer containing the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1167999

Country of ref document: HK

C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: Bielawska Alicja

Inventor after: Bai Aiping

Inventor after: Szulc Zdzislaw M

Inventor after: Hannun Yusef A

Inventor after: J. Norris

Inventor after: Liu Xiang

Inventor before: Bielawska Alicja

Inventor before: Bai Aiping

Inventor before: Szulc Zdzislaw M

Inventor before: Hannun Yusef A

Inventor before: J. Norris

Inventor before: Xiang Liu

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: ALICJA BIELAWSKA BAI AIPING SZULC ZDZISLAW M. HANNUN YUSEF A. JAMES NORRIS XIANG LIU TO: ALICJA BIELAWSKA BAI AIPING SZULC ZDZISLAW M. HANNUN YUSEF A. JAMES NORRIS LIU XIANG

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1167999

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150401

Termination date: 20211106

CF01 Termination of patent right due to non-payment of annual fee